# Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

> **NCT03969212** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 4138 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Baloxavir Marboxil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03969212
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-10
- **Primary completion:** 2024-05-10
- **Final completion:** 2024-05-10
- **Target enrollment:** 4138 (ACTUAL)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03969212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03969212, "Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03969212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*